Oxford Biomedica (LON:OXB – Get Free Report) posted its earnings results on Wednesday. The biopharmaceutical company reported GBX (30.39) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative net margin of 17.85% and a negative return on equity of 48.56%.
Oxford Biomedica Trading Down 2.0%
LON:OXB traded down GBX 10 during trading hours on Wednesday, reaching GBX 483. 650,515 shares of the company were exchanged, compared to its average volume of 1,106,726. The firm has a market cap of £584.66 million, a price-to-earnings ratio of -17.94 and a beta of 1.09. The stock has a 50 day simple moving average of GBX 512.48 and a 200 day simple moving average of GBX 576.03. Oxford Biomedica has a 52-week low of GBX 420 and a 52-week high of GBX 952. The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67.
Oxford Biomedica News Roundup
Here are the key news stories impacting Oxford Biomedica this week:
- Positive Sentiment: Client wins and pipeline visibility improved. Oxford Biomedica reported 17 new clients, described as a record level of commercial wins. Management said the stronger client pipeline improves revenue visibility and supports its existing full-year outlook. OXB wins 17 new clients as its expansion gathers pace
- Positive Sentiment: First-half revenue growth and strategic expansion were encouraging. H1 revenue reached £80.2 million, representing 9% growth, while Oxford Biomedica maintained its FY2026 guidance. The company is also expanding its global quality infrastructure through Veeva Quality Cloud, which could support operational scalability and compliance as its customer base grows. Oxford Biomedica delivers solid H1 growth, record commercial wins
- Neutral Sentiment: Veeva’s customer announcement signals broader adoption of its technology, but the financial benefit to OXB is indirect. Oxford Biomedica’s use of Veeva Quality Cloud may improve quality processes, although the announcement does not materially change near-term revenue expectations. Oxford Biomedica Advances Global Quality Transformation with Veeva Quality Cloud
- Negative Sentiment: Losses remain the main investor concern. Oxford Biomedica reported quarterly EPS of negative 30.39 pence, a negative 17.85% net margin and negative 48.56% return on equity. The first-half loss widened even as revenue increased, highlighting ongoing profitability and execution risks. Oxford Biomedica reiterates sales outlook but half-year loss widens
Wall Street Analyst Weigh In
Check Out Our Latest Report on Oxford Biomedica
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.
Featured Articles
- Five stocks we like better than Oxford Biomedica
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.
